Wound dehiscence · pilonidal sinus
Summary of findings table ‐ Off‐midline closure (Karydakis flap) showed no clear difference in wound dehiscence compared with off‐midline closure (Limberg flap) (low certainty).
1 finding from 1 review
Proportion of wounds healed · pilonidal sinus
It is very uncertain whether summary of findings table ‐ Off‐midline closure changes proportion of wounds healed compared with conventional midline closure (very low certainty).
1 finding from 1 review
Return to work · pilonidal sinus
1 finding from 1 review
Quality of life ‐ not reported · pilonidal sinus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence · pilonidal sinus
Summary of findings table ‐ Off‐midline closure probably leads to lower recurrence rate compared with conventional midline closure (moderate certainty).
1 finding from 1 review
Wound infection · pilonidal sinus
Summary of findings table ‐ Off‐midline closure probably leads to lower wound infection compared with conventional midline closure (moderate certainty).
1 finding from 1 review
Wound dehiscence · pilonidal sinus
Summary of findings table ‐ Off‐midline closure may leads to lower wound dehiscence compared with conventional midline closure (low certainty).
1 finding from 1 review
Return to work · pilonidal sinus
1 finding from 1 review
Quality of life ‐ not reported · pilonidal sinus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to complete healing · pilonidal sinus
1 finding from 1 review
Proportion of wounds healed · pilonidal sinus
Summary of findings table ‐ Off‐midline closure may leads to higher proportion of wounds healed compared with tension‐free midline closure (low certainty).
1 finding from 1 review
All‐cause mortality – at 28 to 30 days, or in‐hospital · people with confirmed COVID‐19
It is very uncertain whether favipiravir changes all‐cause mortality – at 28 to 30 days, or in‐hospital compared with no treatment, supportive treatment, or other antiviral treatment (very low certainty).
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation up to 14 days  · people with confirmed COVID‐19
It is very uncertain whether favipiravir changes progression to invasive mechanical ventilation compared with no treatment, supportive treatment, or other antiviral treatment (very low certainty).
1 finding from 1 review
Need for admission to hospital (if ambulatory) · people with confirmed COVID‐19
Favipiravir showed no clear difference in need for admission to hospital (if ambulatory) compared with no treatment, supportive treatment, or other antiviral treatment (low certainty).
1 finding from 1 review
Time to clinical improvement (defined as time to a 2‐point reduction in patients’ admission status on WHO’s ordinal scale) · people with confirmed COVID‐19
It is very uncertain whether favipiravir changes time to clinical improvement (defined as time to a 2‐point reduction… compared with no treatment, supportive treatment, or other antiviral treatment (very low certainty).
1 finding from 1 review
Progression to oxygen therapy · people with confirmed COVID‐19
Favipiravir showed no clear difference in progression to oxygen therapy compared with no treatment, supportive treatment, or other antiviral treatment (low certainty).
1 finding from 1 review
All adverse events · people with confirmed COVID‐19
Favipiravir may leads to higher all adverse events compared with no treatment, supportive treatment, or other antiviral treatment (low certainty).
1 finding from 1 review
Serious adverse events attributable to the drug · people with confirmed COVID‐19
Favipiravir showed no clear difference in serious adverse events attributable to the drug compared with no treatment, supportive treatment, or other antiviral treatment (low certainty).
1 finding from 1 review
Incidence of acute URTIs during the study period (the number of acute URTIs over a period of time) · children up to the age of 7 at risk of upper respiratory tract infection
Summary of findings table ‐ Vitamin A supplements showed no clear difference in incidence of acute URTIs during the study period (the number of… compared with placebo (low certainty).
1 finding from 1 review
Incidence of acute URTIs during the study period (proportion of participants with an acute URTI) · children up to the age of 7 at risk of upper respiratory tract infection
1 finding from 1 review